Search clinical trials for: SHR2554 SHR1701

Total 57 results

Chinese PLA General Hospital

Recruiting

Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas

Lymphoma | Solid Tumor

China
Chinese PLA General Hospital

Recruiting

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Relapsed or Refractory Hodgkin Lymphoma

China
Yuhan Corporation

Completed

Clinical Trial to Evaluate the Efficacy and Safety of YHP1701

Hypertension and Hyperlipidemia

Korea, Republic of
Yuhan Corporation

Completed

A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706

Type 2 Diabetes Mellitus | Dyslipidemia

Korea, Republic of
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects

Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects

Malignant Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers

Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma

Follicular Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Food Effect Study of SHR2554 on Healthy Chinese Male Adult Subjects

Healthy Adult Subjects

China
Fudan University

Recruiting

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (MULAN)

Breast Cancer | Metastatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Prostate Cancer | Castration-resistant Prostate Cancer

China
Shandong Cancer Hospital and Institute

Unknown

A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment

Non-Small-Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Clinical Study of the Combination of SHR8554 Injection and SHR0410 Injection for the Treatment of Pain After Abdominal Surgery.

Pain
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of HR17031 Injection With Renal Insufficiency

Improved Glycemic Control in Patients With Type 2 Diabetes
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Recruiting

A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms

Relapsed or Refractory Mature Lymphoid Neoplasms

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase 1, Randomized, Placebo-controlled, Single & Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Healthy Chinese Volunteers

Healthy
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in Healthy Subjects

HIV-1 Infection

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A PHASE I, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE DOSE ESCALATION STUDY TO INVESTIGATE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SHR0534 IN HEALTHY VOLUNTEERS

Healthy
Vietlife Healthcare Corporation
Vietnam National Cancer Hospital

Unknown

CH1701 for Prevention and Treatment of Radiation Burns (CH1701)

Cancer

Vietnam
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites

Type 2 Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients

Type 2 Diabetic Patients
Peking University Cancer Hospital & Institute

Recruiting

To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma

Melanoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Pharmacokinetics of HR17031 Injection in Healthy Subjects

Type 2 Diabetes Mellitus

China
Yong Chen

Recruiting

To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma

Melanoma

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of HR17031 Injection With Hepatic Insufficiency

Improved Glycemic Control in Patients With Type 2 Diabetes
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects

Malignant Tumor

China
Yuhan Corporation

Completed

BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects

Healthy Volunteer

Korea, Republic of
Chinese PLA General Hospital

Unknown

Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors

Solid Tumor

China
Henan Cancer Hospital

Active, not recruiting

Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma

Gastric Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes

Type 2 Diabetes

China
Sangart

Completed

Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia

Vascular Disease | Critical Lower Limb Ischemia

Sweden
Ruijin Hospital

Recruiting

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Peripheral T Cell Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Clinical Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery

Pain

China
Yanqiao Zhang
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC (HZ-T-PD1-APA)

Hepatocellular Carcinoma
Peking University

Unknown

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

NK/T-cell Lymphoma
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Clinical Study of SHR8554 Injection for the Treatment of Pain After Abdominal Surgery.

Pain

China
Qilu Hospital of Shandong University

Recruiting

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Gastric Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery

Pain

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Itraconazole Effect Study of SHR2554 on Healthy Chinese Adult Subjects

Healthy Adult Subjects

China
Peking University Cancer Hospital & Institute

Unknown

PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

Melanoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects

Malignant Tumor

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer

Small Cell Lung Cancer Extensive Stage

China
Peking University Cancer Hospital & Institute

Unknown

Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

Melanoma
Wuhan University

Recruiting

SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy (SABRE)

Non-Small Cell Lung Cancer

China
Hunan Cancer Hospital
Suzhou Sheng Diya Biomedical Co., Ltd.

Active, not recruiting

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Adenocarcinoma of the Lung

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Rifampin Effect Study of SHR2554 on Healthy Chinese Adult Subjects

Healthy

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Effect of Itraconazole on Pharmacokinetics (PK) of SHR8554 in Healthy Adult Subjects

Healthy

China

3

Subscribe